An interventional study of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells. in Bone Marrow Transplant Infection, Bronchiolitis Obliterans and Chronic Respiratory Insufficiency, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-29.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening
Hematopoietic stem cell transplantation (HSCT) is used to treat an expanding array of malignant and non-malignant disorders. This is a prospective multicenter study, in pediatric allo-BMT recipients to analyze the spectrum of noninfectious pulmonary complications (PC), to evaluate the prevalence and course of PFT abnormalities before and after transplant, and to detect risk factor for PC.
It's a multicenter prospective study in France. All children under 18 years are included, just before the HSCT. The functional test before the HSCT at 6, 12, 18, 24, 30 and 36 months will be collected and a cardiopulmonary exercise test is done one and three years after the HSCT. Thoracic tomodensitometry is done before the HCT and after at 6, 12, 24 and 36 months.
All data will be collected upon the HSCT, the infections before and after the HSCT, the respiratory symptoms, and the treatment. Bronchia alveolar lavage and serum will be collected and frozen during the study.
The inclusion will be done during two years and children will be following during three years.
The purpose is to evaluate the prevalence, the course of PFT abnormalities before and after transplant, and to detect risk factor for PC.
360 studies on the registry are indexed under Bronchiolitis; 43 are open to participants now.
This study's enrollment of 300 is above the median of 80 across 249 interventional studies indexed under Bronchiolitis.
Browse Bronchiolitis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
Other: late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
Presence of belated non-infectious pulmonary complications
Time frame: 3 years
Presence of risk factors for belated non-infectious pulmonary complications
Time frame: 3 years
Survival three years
Time frame: 3 years
Severity of respiratory disease
Time frame: 3 years
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris